Aging does not follow a single biological script. Some people remain physically active and cognitively resilient well into later life, while others develop chronic inflammation, metabolic disruption and declining organ function much earlier. Scientists increasingly suspect that the trillions of microorganisms living in the intestine help shape these divergent trajectories. A new study in Nature Aging identifies one bacterial species, Bifidobacterium pseudocatenulatum, and a molecule produced by the microbe as potential regulators of healthy aging. In experiments involving human microbiome data and naturally aged mice, the researchers found that the bacterium and its metabolite 5-aminovaleric acid betaine, or 5-AVAB, were associated with reduced age-related inflammation and improvements in several measures of healthspan.
The investigation began with an effort to understand how the gut microbiome changes across the lifespan. Rather than treating the intestinal microbial community as a uniform ecosystem, the researchers analyzed aging patterns in relation to enterotypes, broad microbiome configurations defined by the relative abundance of characteristic bacterial groups. Enterotypes can reflect differences in diet, physiology, geography and host biology, and they may influence how an individual responds to aging. By examining these microbial patterns across multiple Chinese cohorts, including both women and men, the team searched for bacterial species whose age-related behavior was consistent despite differences between populations. This approach highlighted B. pseudocatenulatum as a candidate organism linked to healthier aging.
The bacterium was repeatedly depleted in older individuals across the analyzed cohorts. That observation alone does not prove that the loss of the organism causes aging-related decline; microbial changes can also arise as consequences of altered diet, medication use, intestinal physiology or immune function. To make the data more useful for tracking biological aging, the researchers developed a microbiome-based model called MicroAge. The clock is designed to estimate age-related biological changes from microbial features rather than relying only on chronological age. Such a tool could help distinguish people whose bodies are aging faster or slower than expected, although its predictive value and clinical usefulness will require validation in larger and more diverse populations.
The study’s central experimental test took place in naturally aged mice. The animals received oral treatment with B. pseudocatenulatum, effectively testing whether restoring a microbe that declines with age could influence the aging phenotype. According to the researchers, supplementation improved intestinal homeostasis, the balanced state in which the gut barrier, immune system and resident microbes coexist without excessive inflammatory activation. A healthy intestinal barrier limits the movement of microbial products into circulation. When that barrier becomes more permeable, immune cells can be persistently stimulated, potentially contributing to the low-grade systemic inflammation commonly called inflammaging.
The effects reported by the team extended beyond the intestine. Treated mice showed reduced inflammatory signals in multiple organs, suggesting that the intervention influenced host physiology systemically rather than simply changing the local gut environment. The animals also performed better in tests assessing cognitive and motor abilities, and the treatment extended healthspan—the period of life spent in relatively good functional condition. Healthspan is distinct from lifespan: an intervention may not necessarily produce a dramatic increase in total survival, but it may preserve mobility, cognition and organ function for longer. In this study, the researchers describe B. pseudocatenulatum treatment as improving these functional dimensions in naturally aged animals.
To identify how the bacterium might produce these effects, the scientists examined metabolites generated or influenced by the gut microbial community. Their analysis pointed to 5-AVAB, a small molecule whose levels declined physiologically during human aging. Metabolites are chemically diverse compounds produced by microbes as they process nutrients, as well as molecules modified through interactions between microbial and host metabolism. Because they can enter the circulation and interact with tissues far from the intestine, microbial metabolites are plausible messengers linking the gut to the brain, immune system and other organs. The finding that 5-AVAB decreases with age and is associated with a bacterium depleted in older people strengthened the case for a functional connection.
The researchers then tested 5-AVAB supplementation in aged mice. The compound partially reproduced the broad benefits observed with the live bacterium, including better cognitive and motor performance and lower inflammation across several organs. The word “partially” is important: a single metabolite did not fully recreate the effects of the whole microorganism. A probiotic bacterium can alter the intestinal environment in several ways, including competing with other microbes, changing nutrient availability, influencing the gut barrier and producing multiple bioactive compounds. 5-AVAB may therefore represent one important component of the bacterium’s activity rather than the complete mechanism. The results nonetheless suggest that microbial metabolites could provide a more targeted route for developing interventions than administering a live organism alone.
The proposed B. pseudocatenulatum–5-AVAB axis offers a biological explanation for how age-associated microbial remodeling might contribute to inflammaging. A decline in the bacterium could reduce production of 5-AVAB, weakening signals that help maintain intestinal and systemic balance. In turn, a more permeable or dysregulated gut could promote chronic immune stimulation, while diminished metabolite availability might affect tissues involved in movement and cognition. These links remain mechanistic hypotheses rather than a complete causal map, but the combination of human association data, age-related metabolite measurements and mouse intervention experiments provides a stronger foundation than any single dataset alone.
The findings also illustrate why microbiome-based aging research is moving beyond simple lists of “good” and “bad” bacteria. Microbial effects depend on strain, diet, host genetics, immune status and the chemical environment of the gut. A bacterium that appears beneficial in one setting may behave differently in another, and a treatment that works in mice may not have the same safety or efficacy profile in humans. The study did not establish that taking B. pseudocatenulatum or 5-AVAB can extend human life or prevent age-related disease. Human clinical trials will be needed to determine appropriate doses, treatment duration, long-term safety and whether the effects can be reproduced across populations.
Even with those limitations, the work presents a potentially influential framework for healthy-aging research. MicroAge could eventually help researchers identify biological aging patterns and select participants for intervention studies, while the depletion of B. pseudocatenulatum provides a measurable microbial feature to investigate. The metabolite 5-AVAB may also become a candidate biomarker or therapeutic compound, provided future studies clarify how it acts in human tissues. Together, the findings suggest that aging may be influenced not only by the organisms living in the gut but also by the chemical messages they produce. Restoring a missing microbial signal, rather than attempting to eliminate aging altogether, could become one strategy for preserving function and reducing the chronic inflammation that undermines later life.
Subject of Research: The role of the gut bacterium Bifidobacterium pseudocatenulatum and its metabolite 5-aminovaleric acid betaine in healthy aging, inflammaging and healthspan.
Article Title: A geroprotective probiotic and its functional metabolite counteract inflammaging to extend healthspan
Article References: Lu, X., Ping, J., Han, Z. et al. A geroprotective probiotic and its functional metabolite counteract inflammaging to extend healthspan. Nature Aging (2026). https://doi.org/10.1038/s43587-026-01181-4
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s43587-026-01181-4
Keywords: gut microbiome, healthy aging, inflammaging, Bifidobacterium pseudocatenulatum, 5-AVAB, probiotics, healthspan, MicroAge, microbial metabolites, cognitive aging
Tags: 5-aminovaleric acid betaine (5-AVAB) role in agingand microbiomeBifidobacterium pseudocatenulatum and inflammationdietgeographygut microbiome and healthspaninflammation reduction through probioticsintestinal microbiota and metabolic healthlongevity and gut microbiota interactionsmicrobial metabolites and healthy agingmicrobiome changes across lifespanmicrobiome enterotypes and age-related healthmicrobiome-based interventions for agingProbiotic bacteria and aging
